蔓迪国际递表港交所 华泰国际为保荐人

Core Viewpoint - Mandi International has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor, positioning itself as a leading professional consumer pharmaceutical company in China focused on skin health and weight management solutions [1] Company Overview - Mandi International has established a leadership position in the broader skin health industry, particularly in the hair health sector [1] - The company's flagship product, the Mandi series of minoxidil-based hair loss treatment products, has ranked first in the Chinese hair loss medication market and the minoxidil drug market for ten consecutive years since 2014, according to Zhi Shi Consulting data [1] Market Position - In 2024, the market share of the Mandi series products in the Chinese hair loss medication market and the minoxidil drug market is approximately 57% and 71%, respectively [1] - In March 2025, Mandi International launched the Mandi anti-hair loss shampoo, which is the first functional anti-hair loss shampoo in China containing the ingredient Unodex. The product sold over 500,000 bottles in its first six months [1]